Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS001 in advanced urothelial carcinoma after standard therapy failure
CTR20170347Phase 2Active
- Sponsor
- Junshi Biosciences
- Start
- Apr 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in transitional cell carcinoma of the bladder (TCC), Renal pelvis urothelial carcinoma (UTUC), ureteral urothelial carcinoma, urethral urothelial carcinoma, sponsored by Junshi Biosciences. Started Apr 2017; status: active.
02
Drugs
toripalimab
03
Conditions
transitional cell carcinoma of the bladder (TCC)Renal pelvis urothelial carcinoma (UTUC)ureteral urothelial carcinomaurethral urothelial carcinoma
Beyond the preview
Go deeper on CTR20170347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170347.